Keep A Close Eye Here: Lombard Medical (EVAR), Tuniu Corp (TOUR), Echo Therapeutics (ECTE)

Posted In Business, Healthcare - By David Francis On Wednesday, September 24th, 2014 With 0 Comments

Dallas, Texas 09/24/2014 (ustradevoice) – Lombard Medical Inc (NASDAQ:EVAR) has announced teaming up with Society for Vascular Surgery Patient Safety Organization (SVS PSO) together with M2S Inc. The collaboration involves a post-marketing surveillance program that the U.S. Food and Drug Administration require for Aorfix. The product, Aorfix, is an endovascular stent graft designed for the treatment of AAA. The drug has been used in over 3,000 patients worldwide since its first regulatory approval. Analysts are seemingly bullish on Lombard Medical (EVAR). BTIG Research launched coverage of the stock with a “buy” recommendation and issued $9 target price on it. However, shares of Lombard Medical Inc (NASDAQ:EVAR) remain down more than 25% so far this year.

Tuniu Corp (NASDAQ:TOUR) and a subsidiary of China Three Gorges Corporation have come together for a noble goal. Tuniu and China Three Gorges Project will jointly launch advertisement campaigns to promote Three Gorges Dam to the millions of Chinese leisure seekers. That agreement on joint marketing efforts comes after the two entities agreed to work together towards allowing travelers to make reservations through Tuniu’s online customer services. The customer service platform provided by Tuniu Corp (NASDAQ:TOUR) includes website and mobile app. Shares of Tuniu Corp (NASDAQ:TOUR) jumped up almost 4% early today on the back of the collaboration news.

Echo Therapeutics Inc (NASDAQ:ECTE) has turned into a falling knife, losing almost 74% early today as investors head for the exit door. The management of Echo Therapeutics Inc (NASDAQ:ECTE) recently unleashed bad news even though they were honest. They said that they were suspending operations because of liquidly constraints. Suspending operations means that there would be no clinical programs, product development, research or even manufacturing. The move was informed by a review of the Echo Therapeutics Inc (NASDAQ:ECTE)’s financial health that revealed the company could not fund its operations beyond this month. Echo Therapeutics Inc (NASDAQ:ECTE)’s poor financial position has persisted even after it undertook drastic cost-cutting measures, reduced workers and chopped capital expenses.

About the Author

- David Francis earned a bachelor of arts degree in history from the New Orleans University and a master of arts degree in international relations from North Eastern University

Leave a comment

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>